1991
Journal of Cardiopulmonary Rehabilitation
Author Index

Aalto-Setälä L, 221
Allison TG, 192, 360
Anderson LJ, 360
Arstila M, 221

Balady GJ, 39, 343
Ben-Ari E, 145
Berra K, 8
Birkimer JC, 261
Birkimer SJ, 261
Blumenthal JA, 169
Bogenhagen W, 176
Bonzheim K, 99
Burns PR, 176

Comoss P, 283
Conlin NC, 255
Conolly A-M, 159
Curtis AB, 232

Dennis C, 128
DeSantis C, 392
Dougherty SM, 365
Dubach P, 29
Dykstra S, 176

Einerson J, 176
Ellis B, 227

Fell RD, 353
Forney RC, 392
Foster C, 132, 255, 373
Franklin BA, 99, 213
Froelicher ES, 16
Froelicher VF, 5, 29, 75

Gau GT, 192, 360
Gordon S, 99
Greenland P, 197

Hall LK, 3, 79
Hämäläinen H, 221
Hanson P, 176
Härmälä V, 221
Hasara LC, 392
Hoffman MD, 365
Holland JL, 392

Kaarsalo E, 221
Kallio V, 221
Katch VL, 386
Kelsey MA, 248
Keyser RE, 378
Kirby TE, 248
Knuts L-R, 221

LaFontaine T, 341
Laurila S, 221

Leier CV, 248
Leon AS, 46, 182
Leutholtz BC, 378
Levandoski SG, 365
Lowenthal DT, 132
Lucas M, 261

Mahler DA, 58
McConnell TR, 255
Miller TD, 360
Miller TM, 192
Moberg CH, 378
Morris C, 75
Muri AJ, 360

Nau KL, 386

O'Donnell DE, 58
Oldridge NB, 115

Parks B, 176
Pease MO, 176
Pels AE III, 132
Perdue ST, 16
Pere E, 221
Pickering K, 353
Pivirotto JM, 164
Pollock ML, 5, 132

Ries AL, 23, 227
Robbins B, 240
Rod J, 132
Romeo KC, 214
Rothbaum D, 145

Saccucci MS, 214
Schmidt DH, 132
Schwartz L, 159
Sheldahl LM, 365
Squires RW, 84, 192, 360
Stoiber J, 132
Suarez EC, 169
Sullivan MJ, 108
Swank A, 353

Thompson NN, 255, 373
Timmis GC, 99
Tristani FE, 365
Tsai AC, 386

Van Camp SP, 64
von Duvillard SP, 164

Wallace DJ, 392
Weiner DA, 39
Wendt VE, 378
Wenger NK, 93
Wilke NA, 365

1991
Journal of Cardiopulmonary Rehabilitation Subject Index

Angioplasty, percutaneous transluminal, clinical and exercise considerations after, 145–149
Automatic implantable cardioverter defibrillator, 392

Beta blockers, affecting responses to exercise, 132–142
Blood pressure
advances in hypertension management, 182–189
compliance with programs affecting, 119
exercise affecting, 52–54
exertional hypotension in exercise testing, 32
in hostile postinfarction patients, 169–174
Bypass surgery, exercise testing after, in symptomatic patients, 33

Calcium channel blockers, after myocardial infarction, **348**
Cholesterol levels
compliance with programs affecting, 118–119
costs of hypercholesterolemia treatment, 130
exercise affecting, 50–52
in rehabilitation program graduates, 264
Community approach in rehabilitation, 221–226
Compliance with rehabilitation services, 115–124
Computer use, in exercise testing, 34–35
Continuous positive airway pressure, during exercise in pulmonary patients, 58–60
Coronary angioplasty, percutaneous transluminal, clinical and exercise considerations after, 145–149
Coronary artery disease
efficacy of rehabilitation programs in, 197–201
resistance training in, 99–105
risk factors affected by exercise, 46–55
stable, exercise testing in, 31–32
Coronary heart disease, 378
Cost-effectiveness of cardiac rehabilitation, 128–131
after percutaneous transluminal angioplasty, 147–148
Counseling programs, costs of, 130

Diabetes mellitus, exercise in, 54–55
Drug therapy in hypertension, individualized, 187–189

Education programs
and compliance with rehabilitation programs, 117–118
costs of, 130
guidelines for, 81
Electrocardiography, ST segment in exercise testing, 33–34
Ethnic and gender differences, in cardiac rehabilitation, 214–219
Exercise
and heart rate in pacemaker patients, 232–237
in rehabilitation program graduates, 264
Exercise testing
after bypass surgery, in symptomatic patients, 33
after lung transplantation, 192–196
beta blockers affecting responses to, 132–142
computer scores in, 34–35
critique on methodology of, 16–21
current status of, 75–77
exertional hypotension in, 32
expired gas analysis in, 35
graded, in heart failure, 248–254
handrail support affecting, 255–259
in women, 164–168
in stable coronary heart disease, 31–32
postinfarction, 30–31
protocols in, 36–37
recent advances in, 29–37
risk assessment in, 39–42
silent ischemia in, 32–33
ST segment depression in, 33–34
submaximal, target heart rate in, 159–162
ventricular tachycardia in, 35–36
Exercise test responses to recreational activities, 373
Exercise training
after cardiac transplantation, 85–89
after percutaneous transluminal angioplasty, 145–149
and reduced risk of coronary heart disease, 46–55
compliance with, 120–122
efficacy of, 197–201
evaluation of tapes in, 176–181
in chronic obstructive pulmonary disease, 58–63
in severe systolic left ventricular dysfunction, 108–113
resistance training in, 99–105
risk stratification in, 39–44
unsupervised and supervised, comparisons of, 94–95
upper extremity in, 227–231

Gender and ethnic differences in cardiac rehabilitation, 214–219
Glucose-insulin dynamics, exercise affecting, 54–55

Heart failure
graded exercise testing in, 248–254
and severe systolic left ventricular dysfunction, 108–113
Heart rate
response to exercise in pacemaker patients, 232–237
target rate in submaximal exercise testing, 159
High-density lipoprotein cholesterol, changes in, consequent to smoking cessation, **353**
Hypertension
advances in management of, 182–189
compliance with programs affecting, 119
exercise affecting, 52–54
Hypotension, exertional, in exercise testing, 32

Infarction. *See* Myocardial infarction
Internships, 398
Ischemia, silent, in exercise testing, 32–33

Journal of Cardiopulmonary Rehabilitation, 10 years in retrospect, 5–6

Lipid levels, exercise affecting, 50–52
Lung transplantation, exercise testing after, 192–196

Myocardial infarction
and community approach in rehabilitation, 221–226
and compliance with rehabilitation programs, 115–124
and risk assessment in survivors, 42–43
efficacy of rehabilitation programs in, 197–201
new patterns of rehabilitation in, 93–98
prognostic studies of survival in, 16–21

Obesity, exercise affecting, 49–50
Obstructive pulmonary disease, chronic
exercise training in, 58–63
rehabilitation programs in, 23–28
respiratory muscle training in, 61–63

upper extremity, 227–231
Omega-3 supplementation, 386

Pacemakers, and heart rate response to exercise, 232–237
Plasma lipid values and heart disease, 386
Practice, introduction, **396**
Propranolol, affecting responses to exercise, 132–142
Psychosocial factors
in behavior after percutaneous transluminal angioplasty, 147
in blood pressure responses of hostile postinfarction patients, 169–174
in exercise-based rehabilitation, 201
in social work services, 240–247
Pulmonary patients. *See* Obstructive pulmonary disease, chronic

Rehabilitation programs
after cardiac transplantation, 84–91
compliance with, 115–124
cost-effectiveness of, 128–131
current status of, 75–77
efficacy of, 197–201
ethnic and gender factors in, 214–219
guidelines for, 79–82
historical perspectives and future needs in, 8–14
new patterns in, 93–98
pulmonary, components and results of, 23–28
safety of, 64–69
Resistance training, benefits of, 99–105
Respiratory muscle training, in chronic obstructive pulmonary disease, 61–63
Risk assessment, in cardiac rehabilitation, 39–44
Risk factors
coexistence with hypertension, 186–187
compliance with programs affecting, 118–122
exercise affecting, 46–55
status of rehabilitation program graduates, 261–267

Smoking cessation
compliance with, 119
costs of programs for, 130
Social work services, benefits of, 240–247
Stearic acid, **346**

Tachycardia, ventricular, in exercise testing, 35–36
Theophylline, 350
Transplantation
of heart, rehabilitation after, 84–91
of lung, exercise testing after, 192–196
Treadmill exercise
graded tests in heart failure, 248–254
handrail support affecting, 255–259
in women, 164–168
prediction of functional capacity in, 255–259

Upper extremity training, transfer effect, **365**

Ventricular dysfunction
graded exercise tests in, 248–254
severe systolic, 108–113
Ventricular tachycardia, in exercise testing, 35–36
Video exercise tapes, evaluation of, 176–181

Work activity
after percutaneous transluminal angioplasty, 146–147
early return to, after infarction, 130–131
Weight training during phase II rehabilitation, 360